Forte Biosciences (FBRX) Non Operating Income (2016 - 2026)
Forte Biosciences (FBRX) reported Non Operating Income of $676000.0 for Q1 2026, up 44.44% year-over-year from $468000.0 in Q1 2025, and up 135.67% quarter-over-quarter from -$1.9 million in Q4 2025.
Forte Biosciences (FBRX) Non Operating Income (2016 - 2026) Analysis & Trends
Forte Biosciences (FBRX) has 11 years of Non Operating Income data on file, last reported at $676000.0 in Q1 2026.
- Non Operating Income for Q1 2026 came in at $676000.0, up 44.44% year-over-year; the trailing twelve-month figure through Mar 2026 was -$188000.0 (down 115.56% YoY), and the FY2025 annual result was -$396000.0, down 135.23% from the prior year.
- Non Operating Income climbed to $676000.0 in Q1 2026 per FBRX's latest filing, from -$1.9 million in the prior quarter.
- Over five years, Non Operating Income peaked at $701000.0 in Q3 2025 and troughed at -$1.9 million in Q4 2025.
- A 5-year average of $67352.9 and a median of $196000.0 in 2024 frame the typical range for Non Operating Income.
- The sharpest annual moves came in 2023 and 2025: Non Operating Income jumped 1034.78% in 2023, then tumbled 1066.84% in 2025.
- A 5-year view of Non Operating Income shows it stood at -$100000.0 in 2022, then tumbled by 515.0% to -$615000.0 in 2023, then surged by 131.87% to $196000.0 in 2024, then plunged by 1066.84% to -$1.9 million in 2025, then jumped by 135.67% to $676000.0 in 2026.
- Business Quant data shows FBRX's Non Operating Income at $676000.0 in Q1 2026, -$1.9 million in Q4 2025, and $701000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 5.75 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 444,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 9.35 Mn |
| 10 | Forte Biosciences | 70.77 Mn | 12.55 Mn | - | 676,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 676,000.00 |
| Dec 31, 2025 | -1.90 Mn |
| Sep 30, 2025 | 701,000.00 |
| Jun 30, 2025 | 330,000.00 |
| Mar 31, 2025 | 468,000.00 |
| Dec 31, 2024 | 196,000.00 |
| Sep 30, 2024 | 237,000.00 |
| Jun 30, 2024 | 307,000.00 |
| Mar 31, 2024 | 384,000.00 |
| Dec 31, 2023 | -615,000.00 |
| Sep 30, 2023 | 261,000.00 |
| Jun 30, 2023 | 138,000.00 |
| Mar 31, 2023 | 102,000.00 |
| Dec 31, 2022 | -100,000.00 |
| Sep 30, 2022 | 23,000.00 |
| Jun 30, 2022 | -15,000.00 |
| Mar 31, 2022 | -53,000.00 |
| Dec 31, 2021 | -42,000.00 |
| Sep 30, 2021 | -52,000.00 |
| Jun 30, 2021 | -65,000.00 |